Cargando…

Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection

INTRODUCTION: Treating systemic inflammation caused by SARS-COV 2 (COVID-19) has become a challenge for the clinician. Corticosteroids have been the turning point in the treatment of this disease. Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarriá-Landete, Antonio J., Crespo-Matas, José A., Domínguez-Quesada, Inmaculada, Castellanos-Monedero, Jesús J., Marte-Acosta, Dinés, Arias-Arias, Ángel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212640/
https://www.ncbi.nlm.nih.gov/pubmed/35718548
http://dx.doi.org/10.1016/j.medcli.2022.02.025
_version_ 1784730647577755648
author Sarriá-Landete, Antonio J.
Crespo-Matas, José A.
Domínguez-Quesada, Inmaculada
Castellanos-Monedero, Jesús J.
Marte-Acosta, Dinés
Arias-Arias, Ángel J.
author_facet Sarriá-Landete, Antonio J.
Crespo-Matas, José A.
Domínguez-Quesada, Inmaculada
Castellanos-Monedero, Jesús J.
Marte-Acosta, Dinés
Arias-Arias, Ángel J.
author_sort Sarriá-Landete, Antonio J.
collection PubMed
description INTRODUCTION: Treating systemic inflammation caused by SARS-COV 2 (COVID-19) has become a challenge for the clinician. Corticosteroids have been the turning point in the treatment of this disease. Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone at doses of 6 mg/day shows a reduction on morbidity in patients requiring added oxygen therapy. However, both the start day or what kind of corticosteroid, are still questions to be clarified. Since the pandemic beginning, we have observed large differences in the type of corticosteroid, dose and initiation of treatment. Our objective is to assess the predictive capacity of the characteristics of patients treated with methylprednisolone pulses to predict hospital discharge. MATERIALS AND METHODS: We presented a one-center observational study of a retrospective cohort. We included all patients admitted between 03/06/2020 and 05/15/2020 because of COVID-19. We have a total number of 1469 patients, of whom 322 received pulses of methylprednisolone. Previous analytical, radiographic, previous disease data were analyzed on these patients. The univariant analysis was performed using Chi-squared and the T test of Student according to the qualitative or quantitative nature of the variables respectively. For multivariate analysis, we have used binary logistic regression and ROC curves. RESULTS: The analysis resulted statistically significant in dyspnea, high blood pressure, dyslipidemia, stroke, ischemic heart disease, cognitive impairment, solid tumor, C-reactive protein (CRP), lymphopenia and d-dimer within 5 days of admission. Radiological progression and FIO(2) input are factors that are associated with a worst prognosis in COVID-19 that receive pulses of methylprednisolone. Multivariate analysis shows that age, dyspnea and C-reactive protein are markers of hospital discharge with an area below the curve of 0.816. CONCLUSIONS: In patients with methylprednisolone pulses, the capacity of the predictive model for hospital discharge including variables collected at 5 days was (area under the curve) 0.816.
format Online
Article
Text
id pubmed-9212640
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier España, S.L.U.
record_format MEDLINE/PubMed
spelling pubmed-92126402022-06-22 Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection Sarriá-Landete, Antonio J. Crespo-Matas, José A. Domínguez-Quesada, Inmaculada Castellanos-Monedero, Jesús J. Marte-Acosta, Dinés Arias-Arias, Ángel J. Med Clin (Barc) Original Article INTRODUCTION: Treating systemic inflammation caused by SARS-COV 2 (COVID-19) has become a challenge for the clinician. Corticosteroids have been the turning point in the treatment of this disease. Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone at doses of 6 mg/day shows a reduction on morbidity in patients requiring added oxygen therapy. However, both the start day or what kind of corticosteroid, are still questions to be clarified. Since the pandemic beginning, we have observed large differences in the type of corticosteroid, dose and initiation of treatment. Our objective is to assess the predictive capacity of the characteristics of patients treated with methylprednisolone pulses to predict hospital discharge. MATERIALS AND METHODS: We presented a one-center observational study of a retrospective cohort. We included all patients admitted between 03/06/2020 and 05/15/2020 because of COVID-19. We have a total number of 1469 patients, of whom 322 received pulses of methylprednisolone. Previous analytical, radiographic, previous disease data were analyzed on these patients. The univariant analysis was performed using Chi-squared and the T test of Student according to the qualitative or quantitative nature of the variables respectively. For multivariate analysis, we have used binary logistic regression and ROC curves. RESULTS: The analysis resulted statistically significant in dyspnea, high blood pressure, dyslipidemia, stroke, ischemic heart disease, cognitive impairment, solid tumor, C-reactive protein (CRP), lymphopenia and d-dimer within 5 days of admission. Radiological progression and FIO(2) input are factors that are associated with a worst prognosis in COVID-19 that receive pulses of methylprednisolone. Multivariate analysis shows that age, dyspnea and C-reactive protein are markers of hospital discharge with an area below the curve of 0.816. CONCLUSIONS: In patients with methylprednisolone pulses, the capacity of the predictive model for hospital discharge including variables collected at 5 days was (area under the curve) 0.816. Elsevier España, S.L.U. 2022-12-23 2022-06-17 /pmc/articles/PMC9212640/ /pubmed/35718548 http://dx.doi.org/10.1016/j.medcli.2022.02.025 Text en © 2022 Elsevier España, S.L.U. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Sarriá-Landete, Antonio J.
Crespo-Matas, José A.
Domínguez-Quesada, Inmaculada
Castellanos-Monedero, Jesús J.
Marte-Acosta, Dinés
Arias-Arias, Ángel J.
Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title_full Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title_fullStr Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title_full_unstemmed Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title_short Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection
title_sort predicting the response to methylprednisolone pulses in patients with sars-cov-2 infection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212640/
https://www.ncbi.nlm.nih.gov/pubmed/35718548
http://dx.doi.org/10.1016/j.medcli.2022.02.025
work_keys_str_mv AT sarrialandeteantonioj predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection
AT crespomatasjosea predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection
AT dominguezquesadainmaculada predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection
AT castellanosmonederojesusj predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection
AT marteacostadines predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection
AT ariasariasangelj predictingtheresponsetomethylprednisolonepulsesinpatientswithsarscov2infection